Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
This is a multicenter, open-label phase I/II study for the first-line treatment of advanced cervical cancer.
Official title: A Phase I/II Study to Evaluate Safety and Pharmacokinetics and Initial Efficacy of ZG005 in Combination With Paclitaxel Plus Cisplatin/Carboplatin ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2024-03-27
Completion Date
2026-05
Last Updated
2024-04-02
Healthy Volunteers
No
Conditions
Interventions
ZG005 Powder for Injection
ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
Paclitaxel
IV infusion
Bevacizumab
IV infusion
Cisplatin
IV infusion
Carboplatin
IV infusion
Locations (1)
Zhejiang Cancer Hospital
Zhejiang, Hangzhou, China